Collaboration brings new ArcLight Academy training programs to The University of Texas at San Antonio (UTSA) Professional and Continuing Education (PaCE) students and staff starting this fall. Enhance your education with new programs offering grants and paid tuition, which are available to most applicants. SAN ANTONIO–(BUSINESS WIRE)–#EMT–The University of Texas at San Antonio (UTSA) Professional … [Read more…]
FOSTER CITY, Calif.–(BUSINESS WIRE)–Geron Corporation (Nasdaq: GERN), a commercial stage biopharmaceutical company, today reported that it has granted an equity award in the form of stock options to purchase 11,000,000 shares of common stock to Harout Semerjian, Geron’s new President and Chief Executive Officer, as an inducement material to his acceptance of employment with Geron. … [Read more…]
DUBLIN–(BUSINESS WIRE)–The “Conflict Management for Pharmaceutical Executives Training Course” training has been added to ResearchAndMarkets.com’s offering. Effective conflict management is essential for pharmaceutical executives to navigate the complexities of a dynamic, globalised industry. This four-module webinar equips participants with vital strategies and tools to identify, address, and resolve workplace conflicts. Key topics include understanding the … [Read more…]
MURFREESBORO, Tenn.–(BUSINESS WIRE)–National HealthCare Corporation (NYSE American: NHC), the nation’s oldest publicly traded senior health care company, announced today net operating revenues for the quarter ended June 30, 2025 totaled $374,910,000 compared to $300,658,000 for the quarter ended June 30, 2024, an increase of 24.7%. The increase in net operating revenues for the second quarter … [Read more…]
MOBILE, Ala.–(BUSINESS WIRE)–TruBridge, Inc. (NASDAQ: TBRG), a healthcare solutions company, today announced financial results for the second quarter and six months ended June 30, 2025. Second Quarter 2025 Highlights* All comparisons are to the quarter ended June 30, 2024, unless otherwise noted Total bookings of $25.6 million compared to $23.3 million Total revenue of $85.7 … [Read more…]
WILMINGTON, Mass.–(BUSINESS WIRE)–Ametros, the industry leader in professional administration of medical insurance claims settlements, is pleased to announce the appointments of Hollie Lamboy as Vice President of Member Experience and Lena Lini as Vice President of Member Operations, two newly created roles designed to strengthen the company’s member-focused strategy. These strategic hires reflect Ametros’ unwavering … [Read more…]
Actively enrolling patients with lupus nephritis (LN), systemic lupus erythematosus (SLE) and systemic sclerosis (SSc) in Phase 1 clinical trial of ADI-001 in autoimmune diseases On track to report preliminary clinical data for ADI-001 in 2H/2025 Enrollment now open for patients with idiopathic inflammatory myopathy (IIM), stiff person syndrome (SPS) and anti-neutrophil cytoplasmic autoantibody associated … [Read more…]
DUBLIN–(BUSINESS WIRE)–The “Chondrosarcoma Market – A Global and Regional Analysis: Focus on Type, Treatment Type, and Region – Analysis and Forecast, 2025-2035” report has been added to ResearchAndMarkets.com’s offering. Chondrosarcoma is a rare malignant tumor of cartilage-forming tissue, most commonly affecting bones such as the pelvis, femur, and humerus. Subtypes include conventional, dedifferentiated, mesenchymal, and … [Read more…]
Community Event to Support People with Breast Cancer, Raise Funds for Research and Advocacy Takes Place September 13, 2025 DETROIT–(BUSINESS WIRE)–Susan G. Komen®, the world’s leading breast cancer organization, will convene breast cancer survivors, those living with metastatic breast cancer (MBC) and supporters at the 2025 Susan G. Komen Detroit Race for the Cure. This … [Read more…]
– Continued rapid progress with Phase 1 ELIMINATE-B trial evaluating PBGENE-HBV for Hepatitis B; Announced safety and efficacy for Cohort 1 and safety data for Cohort 2 – PBGENE-HBV demonstrated substantial antiviral activity in all Cohort 1 patients, with best responses achieving a 47-69% reduction in Hepatitis B surface antigen (HBsAg) and durable HBsAg reduction … [Read more…]
